medigraphic.com
Revista Mexicana de Coloproctología Enfermedades del Ano, Recto y Colon

2005, Number 1

<< Back Next >>

Rev Mex Coloproctol 2005; 11 (1)

Hyperbaric Oxygenation as Adjuvant Treatment in CUCI

Aguilar MF, Aguila MJ, Llanes DG, García DBL, Santana PS

Language: Spanish
References: 13
Page: 40-46
PDF size: 60.60 Kb.


ABSTRACT

Purpose: The results on the clinical and endoscopic evolution of ulcerative colitis (UC) of the treatment with Hyperbaric Oxygenation (HBO). Methods: Are presented in this article. 43 patients were recruited in the Service of Coloproctology of the Clinical-Surgical Hospital “Hermanos Ameijeiras” (La Habana, Cuba) for this study. All the patients were receiving Azulfidine: 4 grams a day. The 43 recruited patients were assigned to any of two groups: Group A: Treatment-Group: 23 subjects received 15 HBO sessions of 1 hour of duration each one. Group B: Control-Group: 20 patients. There was improvement in 8 out of 10 indicators selected to assess the effectiveness of HBO in achieving relief of the UC clinical symptoms, and improvement of endoscopically observed lesions. Results: There were dramatic changes in the expression of pain, and the passage of blood and mucus in the stools, and in the vascular pattern of the mucosa, and the presence of blood, mucus and pus in the mucosa. Conclusion: It is concluded that HBO can be a useful adjuvant therapeutical tool in the treatment of UC.


REFERENCES

  1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.

  2. Dignass AU, Baumgart DC, Sturm A. Review article: the aetiopathogenesis of inflammatory bowel disease—immunology and repair mechanisms. Aliment Pharmacol Ther 2004; 20(Suppl 4): 9-17.

  3. Jain KK. Physical, physiological, and biochemical aspects of hyperbaric oxygenation. In: Textbook of Hyperbaric Medicine. (Editors: Jain KK, Neubauer R, Correa JG, Camporesi EM). Hogrefe & Huber. Seattle: 1996: 11-26.

  4. Oriani G, Michael M, Marroni A, Longoni C. Physiology and physiopathology of hyperbaric oxygen. In: Handbook on Hyperbaric Medicine. (Editors: Oriani G, Marroni A, Wattel F). Springer. Milán: 1996: 1-34.

  5. Hanauer SB. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther 2004; 20(Suppl 4): 97-101.

  6. Martínez CH, Santana PS. Manual de Procedimientos Bioestadísticos. Editorial de Ciencias Médicas. La Habana: 1990.

  7. Karlinger K, Gyorke T, Mako E, Mester A, Tarjan A. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000; 35: 154-67.

  8. Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20(Suppl 4): 24-30.

  9. Hanauer SB. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20(Suppl 4): 60-5.

  10. Poliakova LV, Lukich VL, Grigorieva GA. Hyperbaric oxygenation and drug therapy in treatment of nonspecific ulcerative colitis and Crohn’s disease. Fiziol Zh 1991; 37: 120-3.

  11. Buchman AL, Fife C, Torres C, Smith L, Aristizibal J. Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol 2001; 33: 337-9.

  12. Rachmilewitz D, Karmeli F, Okon E, Rubenstein I, Better Os. Hyperbaric oxygen: a novel modality to ameliorate experimental colitis. Gut 1998; 43: 512-8.

  13. Gulec B, Yasar M, Yildiz S, Oter S, Akay C, Devecý C, Sen D. Effect of Hyperbaric oxygen on experimental acute distal colitis. Physiol Res 2004; 53: 493-500.




2020     |     www.medigraphic.com